Overview

Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Evaluate the percentage of clinical objective responses (cOR) in patients with HER2 negative early breast cancer treated with pre operative (neoadjuvant)lapatinib and letrozole
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Lapatinib
Letrozole